Efficacy and Safety of Triazavirin Therapy for Coronavirus Disease 2019: A Pilot Randomized Controlled Trial

No therapeutics have been proven effective yet for the treatment of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To assess the efficacy and safety of Triazavirin therapy for COVID-19, we conducted a randomized, double-blinded controlled...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Xiaoke, Yu, Kaijiang, Wang, Yongchen, Xu, Wanhai, Ma, Hongli, Hou, Yan, Li, Yue, Cai, Benzhi, Zhu, Liying, Zhang, Min, Hu, Xiaoli, Gao, Jingshu, Wang, Yu, Qin, Huichao, Wang, Wenjie, Zhao, Mingyan, Wu, Xia, Zhang, Yong, Li, Lu, Li, Kang, Du, Zhimin, Mol, Ben Willem J., Yang, Baofeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: THE AUTHORS. Published by Elsevier LTD on behalf of Chinese Academy of Engineering and Higher Education Press Limited Company. 2020
Materias:
Research Coronavirus Disease 2019—Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7476906/
https://www.ncbi.nlm.nih.gov/pubmed/32923016
http://dx.doi.org/10.1016/j.eng.2020.08.011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7476906/
https://www.ncbi.nlm.nih.gov/pubmed/32923016
http://dx.doi.org/10.1016/j.eng.2020.08.011

Ejemplares similares